The Oncolytic Virus Therapy Market was valued at approximately USD 3.0 billion in 2025 and is projected to reach USD 9.8 billion by 2035, registering a CAGR of approximately 12.4% from 2026 to 2035. Rising cancer prevalence, increasing investment in oncology research, genetic engineering advancements, and growing interest in personalized cancer treatment are supporting market expansion.
Oncolytic virus therapy uses modified viruses designed to selectively target cancer cells while stimulating an immune response against tumors. This approach is attracting attention as researchers explore alternatives and complements to conventional cancer treatments.
Melanoma represents a major application area, with the segment projected to reach approximately USD 2.5 billion by 2035. Research into oncolytic approaches for melanoma continues to encourage clinical development and investment.
Combination therapies are another important trend. Researchers are investigating the potential of combining oncolytic viruses with immunotherapies, including immune checkpoint inhibitors, to improve antitumor responses.
Genetic engineering is also transforming the field. Advances in viral modification can help researchers improve tumor selectivity, therapeutic activity, and safety profiles.
With increasing clinical research and continued investment in innovative oncology technologies, oncolytic virus therapy is expected to become an increasingly important component of the evolving cancer-treatment landscape.
